Added benefit of saxagliptin/metformin combination is not proven

Drug manufacturer did not submit suitable data in its dossier

2013-04-29

(Press-News.org) The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added benefit versus the current standard treatment. Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any relevant data.

Dual or triple combination therapy possible

The combination is an option for adult patients who do not benefit sufficiently from the commonly used drug metformin or who are already taking saxagliptin and metformin as individual tablets. It can also be used together with insulin if insulin and metformin are insufficient.

Glibenclamide or glimepiride as the appropriate comparator therapy

The Federal Joint Committee (G-BA) has specified metformin in combination with a sulfonylurea (glibenclamide or glimepiride) as the appropriate comparator therapy for saxagliptin/metformin. The triple combination therapy, i.e. saxagliptin/metformin and insulin, was to be compared with metformin and human insulin.

Dual combination: Manufacturer compared saxagliptin/metformin with glipizide

Regarding the dual combination therapy, the manufacturer deviated from the G-BA's specifications and submitted data from an approval study in which the patients in the control group did not receive glibenclamide or glimepiride, but another sulfonylurea, namely glipizide. However, this drug has no longer been approved in Germany since 2007. In addition, the manufacturer did not provide sufficient explanation in its dossier that glipizide is equivalent to the other two sulfonylureas.

Study on triple combination is unsuitable

Regarding the combination with insulin, the manufacturer submitted a study that directly compared saxagliptin/metformin and insulin with metformin und human insulin. But the results of this study cannot be used for the assessment of the added benefit.

The main reason for this is that the insulin therapy could not be tailored sufficiently to the individual patient in the first treatment phase: even though their current insulin therapy was insufficient, patients were neither supposed to change the insulin nor to adapt the dose. But to be able to draw conclusions about the added benefit, the combination of saxagliptin/metformin and insulin would have to be compared with other strategies for optimizing treatment, for example optimizing insulin use.

Not tailoring treatment to the individual patient does not meet the current standard of diabetological practice anyway. Instead, insulin therapy is optimized for the individual patient so that hyperglycaemia and hypoglycaemia do not occur in the first place. So in the study, insulin was not used in a way that would be necessary and appropriate in this indication.

Therefore, there are no study results for either of the two therapeutic indications of the fixed combination saxagliptin/metformin from which an added benefit could be derived.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

### An overview of the results of IQWiG's benefit assessment is given by a executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on saxagliptin/metformin.

The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book V and specific German-language information on the assessment of saxagliptin/metformin. END

ELSE PRESS RELEASES FROM THIS DATE:

Extreme political attitudes may stem from an illusion of understanding

2013-04-29

Having to explain how a political policy works leads people to express less extreme attitudes toward the policy, according to new research published in Psychological Science, a journal of the Association for Psychological Science. The research suggests that people may hold extreme policy positions because they are under an illusion of understanding — attempting to explain the nuts and bolts of how a policy works forces them to acknowledge that they don't know as much about the policy as they initially thought. Psychological scientist Philip Fernbach of the Leeds School ...

Comparing proteins at a glance

2013-04-29

A revolutionary X-ray analytical technique that enables researchers at a glance to identify structural similarities and differences between multiple proteins under a variety of conditions has been developed by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab). As a demonstration, the researchers used this technique to gain valuable new insight into a protein that is a prime target for cancer chemotherapy. "Proteins and other biological macromolecules are moving machines whose power is often derived from how their ...

Sniffing out schizophrenia

2013-04-29

A debilitating mental illness, schizophrenia can be difficult to diagnose. Because physiological evidence confirming the disease can only be gathered from the brain during an autopsy, mental health professionals have had to rely on a battery of psychological evaluations to diagnose their patients. Now, Dr. Noam Shomron and Prof. Ruth Navon of Tel Aviv University's Sackler Faculty of Medicine, together with PhD student Eyal Mor from Dr. Shomron's lab and Prof. Akira Sawa of Johns Hopkins Hospital in Baltimore, Maryland, have discovered a method for physical diagnosis ...

Many stressors associated with fracking due to perceived lack of trust, Pitt finds

2013-04-29

PITTSBURGH, April 29, 2013 – Pennsylvania residents living near unconventional natural gas developments using hydraulic fracturing, known by the slang term "fracking," attribute several dozen health concerns and stressors to the Marcellus Shale developments in their area, according to a long-term analysis by University of Pittsburgh Graduate School of Public Health researchers. Reported health impacts persist and increase over time, even after the initial drilling activity subsides, they noted. The study, which will be published in the May issue of the International Journal ...

Shape-shifting mobile devices

2013-04-29

Prototype mobile devices that can change shape on-demand will be unveiled today [Monday 29 April] and could lay down the foundation for creating high shape resolution devices of the future. The research paper, to be presented at one of the world's most important conferences on human-computer interfaces, will introduce the term 'shape resolution' and its ten features, to describe the resolution of an interactive device: in addition to display and touch resolution. The research, led by Dr Anne Roudaut and Professor Sriram Subramanian, from the University of Bristol's ...

Plants moderate climate warming

2013-04-29

As temperatures warm, plants release gases that help form clouds and cool the atmosphere, according to research from IIASA and the University of Helsinki. The new study, published in Nature Geoscience, identified a negative feedback loop in which higher temperatures lead to an increase in concentrations of natural aerosols that have a cooling effect on the atmosphere. "Plants, by reacting to changes in temperature, also moderate these changes," says IIASA and University of Helsinki researcher Pauli Paasonen, who led the study. Scientists had known that some aerosols ...

Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking

2013-04-29

ORLANDO – Residents living in areas near natural gas operations, also known as hydraulic fracturing, or fracking, are concerned their illnesses may be a result of nearby drilling operations. Twenty-two percent of the participants in a small pilot study surmise that hydrofracking may be the cause of such health concerns as sinus problems, sleeping difficulties, and gastrointestinal problems. The findings will be presented at the American Occupational Health Conference on April 28 in Orlando, Florida. Scientists collected responses from 72 adults visiting a primary care ...

Turtle genome analysis sheds light on the development and evolution of turtle-specific body plan

2013-04-29

April 28, 2013, Shenzhen, China- The Joint International Turtle Genomes Consortium, led by investigators from RIKEN, BGI, and Wellcome Trust Sanger Institute, has completed the genome sequencing of soft-shell turtle (Pelodiscus sinensis) and green sea turtle (Chelonia mydas). These achievements shed new light on the origin of turtles and applied the classical evo-devo model to explain the developmental process of their unique body plan. The findings were published online in Nature Genetics. The evolution of turtles is an enigma in science. Their distinct body design-with ...

Mapping of cancer cell fuel pumps paves the way for new drugs

2013-04-29

For the first time, researchers at Karolinska Institutet in Sweden have managed to obtain detailed images of the way in which the transport protein GLUT transports sugars into cells. Since tumours are highly dependent on the transportation of nutrients in order to be able to grow rapidly, the researchers are hoping that the study published in the scientific magazine Nature Structural & Molecular Biology will form the basis for new strategies to fight cancer cells. In order to be able to fuel their rapid growth, cancer tumours depend on transporter proteins to work at ...

Clarifying the effect of stem cell therapy on cancer

2013-04-29

Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is this modification of blood supply which seems to impact tumor growth. The use of stem cells in treating cancer has been controversial, with some studies finding that stem cells force tumors to enter programmed cell death. However other studies find that stem cells actually promote ...

LAST 30 PRESS RELEASES:

Global cervical cancer vaccine roll-out shows it to be very effective in reducing cervical cancer and other HPV-related disease, but huge variations between countries in coverage

Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds